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ponent of a modified Geller-Seifter operant procedure, while typi-
cals such as haloperidol, chlorpromazine, and thioridazine did not 
(Wiley et al., 1993). The ability of clozapine to increase punished 
responding has also been found in pigeons (Mansbach et al., 1988), 
mice and squirrel monkeys (Spealman and Katz, 1980), suggesting 
it may possess some anxiolytic activity. Olanzapine is found to be 
effective in reducing conditioned freezing, in increasing time spent 
on the open arms of the elevated plus maze as well as that in social 
interaction (Frye and Seliga, 2003) and indecreasing stress-induced 
ultrasonic vocalizations (Siemiatkowski et al., 2001). Both olanzap-
ine and clozapine have been found to increase water licking of an 
electrified water bottle in the Geller-Seifter conflict task (Moore et 
al., 1992), demonstrating that these atypical anti-psychotics may pos-
sess anxiolytic activity. However, there are other reports that fail to 
confirm this anxiolytic activity (Cao and Rodgers, 1997; Fernandez-
Tome et al., 1979; Masson et al., 2003; Shadach et al., 1999). Still others 
even suggest an anxiogenic activity (Karl et al., 2006; Manzaneque et 
al., 2002). This issue is further complicated by other studies show-
1. Introduction
In recent years, atypical anti-psychotic drugs (APDs) such as ris-
peridone, olanzapine and quetiapine have been increasingly used to 
treat anxiety-related disorders in addition to their use in the treat-
ment of psychosis. The results have been mixed (Carson et al., 2004). 
Some case reports suggest that atypicals improve symptoms of 
obsessive-compulsive disorder and panic disorder, while an equal 
number of reports indicate the worsening effects on these disorders 
(Brooke et al., 2005). Preclinical evidence is also inconclusive. Some 
studies have demonstrated ananxiolytic-like activity with the atyp-
icals. For example, clozapine is reported to be effective in attenuat-
ing shock-induced conditioned freezing (Inoue et al., 1996; Ishida-
Tokuda et al., 1996), footshock-induced ultrasonic vocalization 
(DeVry et al., 1993), passive avoidance response (Rasmussen et al., 
2001) and increasing time spent in the central area of an open field 
(Bruhwyler et al., 1990b). It has also been found that clozapine can 
produce a significant increase in responding during the conflict com-
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ABSTRACT
Psychotic fear and anxiety disturbances are seen at a relatively high frequency in patients with schizophrenia. Atypical anti-
psychotics are believed to show superior efficacy in reducing these symptoms. However, clinical and preclinical evidence 
regarding their anxiolytic efficacy has been mixed. In this study, we evaluated the possible anxiolytic property of two atyp-
icals, clozapine and olanzapine, and compared them with typical haloperidol and chlordiazepoxide (a prototype of seda-
tive-anxiolytic drug) in two preclinical models of fear. In Experiment 1, we used a fear-induced passive avoidance and con-
ditioned place aversion paradigm and examined the effects of clozapine (20 mg/kg, sc), haloperidol (0.05 mg/kg, sc) and 
chlordiazepoxide (10mg/kg, ip). In Experiments 2 and 3, we used a two-way active avoidance conditioning paradigm and 
further compared the effects of clozapine (20 mg/kg, sc), haloperidol (0.05 mg/kg, sc), chlordiazepoxide(10mg/kg, ip) and 
three doses of olanzapine (0.5, 1.0, and 2.0 mg/kg, sc). Results show that clozapine and chlordiazepoxide, but not haloperi-
dol, significantly attenuated the shock conditioning-induced place aversion, decreased the amount of defecations and the 
number of the 22-kHz vocalizations. Clozapine also reduced the shock conditioning-induced hyperthermia. Similar to clo-
zapine, olanzapine also significantly decreased the amount of defecations and reduced the shock conditioning-induced 
hyperthermia, but it did not inhibit the 22-kHz vocalizations. This study demonstrates that clozapine and olanzapine pos-
sess an intrinsic anxiolytic property, which is not attributable to its superior anti-“psychotic” effect or its favorable effects 
on motor functions or learning and memory processes. These findings also suggest that the combined use of passive avoid-
ance and active avoidance conditioning models can be useful in better differentiating typical and atypical anti-psychotics 
as well as anxiolytics.
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thus, any beneficial effect resulting from the atypicals may simply 
be attributed to the dose differences. In Experiment 3, using the 
same paradigm and fear response measures as used in Experiment 
2, we investigated the potential anxiolytic property of olanzapine, 
another atypical APD with a similar profile to clozapine, but much 
more widely  used than clozapine, to further examine this issue. We 
also employed 3 different doses of olanzapine to examine any dose-
dependent effects of the most clinically relevant atypical.
2. Materials and methods
2.1.Subjects
Sixty male Sprague-Dawley rats (275-325 g upon arrival, Charles 
River, Montréal, Canada) were used in Experiment 1, 44 male rats 
(250-275 g upon arrival, Charles River, Potage, MI) were used in 
Experiment 2, and 45 male rats (250-275 g upon arrival, Charles 
River, Potage, MI) were used in Experiment 3. They were housed 
two per cage, in 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbon-
ate cages under 12-h light/dark conditions (light on between 8:00 
p.m. and 8:00 a.m. in Experiment 1, and between 6:00 a.m. and 6:00 
p.m. in Experiments 2 and 3). Room temperature was maintained at 
21 ± 1° with a relative humidity of 55-60%. Food and water was avail-
able ad libitum. Animals were allowed at least one week of habitua-
tion to the animal facility before being used in experiments. All pro-
cedures were approved by the animal care committees at either the 
Centre for Addiction and Mental Health (for Experiment 1) or the 
University of Nebraska-Lincoln (for Experiments 2 and 3).
2.2. Apparatus
Two identical two-way shuttle boxes custom designed and man-
ufactured by Med Associates (St. Albans, VT) were used. Each box 
was housed in a ventilated, sound-insulated isolation cubicle (96.52 
cm W × 35.56 cm D × 63.5 cm H). Each box was 64 cm long, 30 cm 
high (from grid floor) and 24 cm wide, and divided into two equal-
sized compartments by an automatic guillotine door (ENV-010B, 
Experiment 1) or a white PVC partition with an arch style door-
way (15 cm high × 9 cm wide at base, Experiments 2 and 3). The 
grid floor consisted of 40 stainless steel rods with a diameter of 0.48 
cm, spaced 1.6 cm apart center to center, through which scrambled 
footshock (US, 0.8 mA) was delivered by a constant current shock 
generator (Model ENV-410B) and scrambler (Model ENV-412). For 
Experiments 2 and 3, illumination was provided by two house-
lights (28V) mounted at the top of each compartment. An ultra-
sonic vocalization detector (ANL-937A) was situated on the right 
side wall of each box. The rat location and locomotor activity was 
detected by a set of 16 photobeams (ENV-256-8P) affixed at the bot-
tom of the box (3.5 cm above the grid floor). The CS was a 74-dB 
white noise produced by a speaker (ENV224 AMX) mounted on the 
ceiling of the cubicle, centered above the shuttle box. All the train-
ing and testing procedures were controlled by Med Associates pro-
grams running on a computer. Background noise (approximately 
68 dB) was provided by a ventilation fan affixed at the top corner of 
each isolation cubicle.
2.3. Drugs and choice of doses
Haloperidol (HAL), 5 mg/ml ampoules (Sabex Inc. Boucheville, 
Quebec, Canada), clozapine (CLZ, gift from National Institute of 
Mental Health’s Chemical Synthesis and Drug Supply Program 
or from Anawa Biomedical Services and Products, Zurich, Swit-
zerland), olanzapine (OLZ, purchased from Toronto Chemicals 
Inc., Ontario, Canada), and chlordiazepoxide (CDP, Sigma Chem-
ical, St. Louis, MO) were used. The injection solutions of haloperi-
dol and chlordiazepoxide were obtained by mixing the drugs with 
sterile water. Clozapine and olanzapine were dissolved in 1-2% gla-
cial acetic acid in sterile water. The doses of haloperidol (0.05 mg/
kg), clozapine (20 mg/kg) and olanzapine (0.5, 1.0, and 2.0 mg/kg) 
ing that even typical APDs also display ananxiolytic property in 
the same behavioral paradigms mentioned above (Allen et al., 1974; 
Greba et al., 2001; Guarraci et al., 2000; Inoue et al., 2005; Inoue et al., 
1996; Johnson, 1970a, b; Joordens et al., 1998; Olivier et al., 2003; Pon-
nusamy et al., 2005; Taukulis et al., 1992).
Other than the procedural differences (species, drug doses, tim-
ing of drug administrations, etc.), several factors may also account 
for this rather confusing group of studies. First, a wide variety of 
behavioral models including both unconditioned (e.g., elevated 
plus maze, open field) and conditioned fear paradigms (e.g., con-
ditioned freezing, fear-potentiated startle) have been used, which 
may not measure the same aspects of fear/anxiety responses and 
may not provide the same assessment of the drug effects. Further-
more, most studies often employ just one behavioral task or mea-
sure, rather than a series of convergent tasks and measurements to 
cross-validate the findings. Second, all APDs have multiple behav-
ioral actions (e.g., motor, emotion, motivation or even cognition), 
the interactions among which may mask the effect size of one spe-
cific effect and influence the way we interpret the data. Finally, the 
intrinsic anti-psychotic effect of the drugs may also impact the mea-
surements of anxiolytic activity, and most previous studies have not 
carefully controlled this influence. Therefore, clinical and preclini-
cal evidence accumulated so far is inadequate to assess the intrin-
sic anxiolytic property of both typical and atypical APDs, and the 
possible advantages of atypicals over typicals in the treatment of 
anxiety disorders or anxiety in schizophrenia have not been deter-
mined.
In light of these observations, the present study further investi-
gated the possible anxiolytic property of typical and atypical APDs 
using a preclinical approach. Specifically, in Experiment 1, we 
used a composite passive avoidance and conditioned place aver-
sion task and examined the effects of acute treatment with clozap-
ine, haloperidol or chlordiazepoxide (one single injection) on vari-
ous conditioned fear responses (e.g. inhibitory passive avoidance, 
ratio of time spent in the shock compartment relative to time in the 
safe compartment, etc.). Haloperidol and clozapine were chosen 
as the representatives of typical and atypical APDs. Chlordiazep-
oxide was chosen as the representative of classic benzodiazepine 
anxiolytics. In Experiment 2, using an active avoidance condition-
ing model (CAR), we compared the effects of repeated treatment 
with these drugs (7 daily repeated injections) on the conditioned 
active avoidance response as well as other associated conditioned 
fear responses (amount of defecation, ultrasonic vocalization, 
change in body temperature) to cross-validate the results from 
Experiment 1 and to extend them to a repeated treatment regimen. 
The CAR model was carefully selected because it is a well-estab-
lished model for the study of anti-psychotic activity (Wadenberg 
and Hicks, 1999). All currently used APDs selectively inhibit con-
ditioned avoidance responding but not escape, whereas anxiolytics 
or antidepressants do not have such selectivity (Arnt, 1982). More 
importantly, in addition to robust avoidance responding, animals 
tested in this model also show various signs of fear and anxiety, 
such as increased body temperature, emission of ultrasonic vocal-
ization (termed 22-kHz calls), and defecation and urination, which 
have been routinely used as reliable measures of conditioned reac-
tive fear as well as to assess anxiolytic properties of psychotropic 
drugs (DeVry et al., 1993; Fanselow, 1986; Godsil et al., 2000; San-
chez, 2003). Thus we were able to use this single behavioral par-
adigm to compare the anxiolytic property of typical and atypical 
APDs (as indexed by their action on various fear responses), while 
properly matching their anti-psychotic property (as indexed by their 
action on active avoidance responding). This latter point is particu-
larly important because one of the problems in previous drug com-
parison studies is that the typical APDs and atypicals often were not 
compared under the same conditions, with the doses for the typi-
cals substantially higher than those of atypicals (Siemiatkowski et 
al., 2001) in terms of their efficacy to produce a clinically compara-
ble level of D2 receptor occupancy (60-80%) (Kapur et al., 2003b) and 
to disrupt avoidance responding to the same extent (Li et al., 2007); 
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the subject was allowed to enter the right compartment and explore 
the whole apparatus for 10 min. The latency to enter the right com-
partment, time spent in each compartment, number of entries to the 
right compartment, and numbers of defecations were recorded.
2.5.1.2.Conditioning (under drug). On the next day, the subject was 
placed in the left compartment of the shuttle box after receiving 
HAL (0.05 mg/kg, -90 min.), CLZ (20 mg/kg, -30min.), CDP (10 mg/
kg, -30 min.) or vehicle injection (distilled water, -90 min.). Thirty 
seconds later, the door was lifted and the subject was allowed to 
enter the right compartment. Once entered, the door was immedi-
ately closed and 10 trials of CS-US were given. The CS was 11 s, 10 
kHz, 85 dB pure tone, while the US was 1 s, 0.8 mA footshock. The 
onset of the US occurred 10 s after the onset of the CS andco-termi-
nated with the CS. The mean intertrial interval was 60 s (40-80s).
2.5.1.3. Post-conditioning test (without drug). Two days after the con-
ditioning, the test was conducted. The basic procedure was exactly 
the same as the baseline test (see Baseline test above) and lasted 10 
min. Similarly, the latency to enter the shock compartment (pas-
sive avoidance latency), time spent in each compartment (max 600 
s), number of entries to the shock compartment, and the numbers 
of defecations were recorded. If the subject failed to enter the right 
compartment within 10 min., a latency of 600 s was assigned.
2.6. Experiment 2: effects of repeated haloperidol, clozapine or chlordiazep-
oxide treatment on conditioned active avoidance responding and various 
conditioned fear responses
To cross-validate the anxiolytic effects of clozapine and chlordiaz-
epoxide observed in Experiment 1, this second experiment used an 
active avoidance conditioning model and examined how repeated 
haloperidol, clozapine or chlordiazepoxide treatment (7 consecutive 
days) differentially affected various conditioned fear responses in 
this model, such as body temperature change (before and after con-
ditioning), 22-kHz USVs, and amount of defections, along with their 
effects on active avoidance responding, an index of an anti-psychotic 
property. This model allowed us to concurrently evaluate and com-
pare the anti-psychotic and potential anxiolytic activities of halo-
peridol and clozapine.
2.6.1. Procedure
In order to adapt rats to the body temperature measuring proce-
dure and injection procedure and to minimize the associated stress, 
all rats were first handled daily and habituated to the body temper-
ature measuring procedure (twice daily, 20 min interval) and injec-
tion procedure for 6 successive days, which was sufficient to obtain 
a stable baseline body temperature (Godsil et al., 2000). Following 
this adaptation phase, all rats were habituated to the CAR boxes for 
2 days (20 min./day) and their body temperatures (twice: before and 
after habituation) and amount of defecations (in mg) were recorded. 
In addition, the “22-kHz” ultrasonic vocalizations (USVs) were also 
recorded. After the habituation, the rats were randomly assigned to 5 
groups: haloperidol (HAL, n = 9), clozapine (CLZ , n = 10), chlordiaz-
epoxide (CDP, n = 10), vehicle (VEH, n = 9) and control (CON, n = 6). 
In the subsequent 7 days, the first 4 groups were trained in a 20-trial 
CAR session/day, whereas the control group continued on the 20 
min. habituation procedure (no CS or US). Before each daily session, 
the rats were injected with HAL (0.05 mg/kg, sc), CLZ (20 mg/kg, 
sc), CDP (10 mg/kg, ip) or vehicle (sterile water for both VEH and 
CON groups, ip or sc), and their body temperatures were recorded 
before being placed in the boxes. HAL and CLZ were administered 
1 h before the training, whereas CDP was administered 0.5 h before. 
Body temperatures were taken again immediately after each test. 
Following the 7 daily drug tests, all rats were continuously tested 
drug-free for an additional 3 sessions under the CS-only condition 
(no US) to assess the long-term drug effects not contaminated by the 
presence of the shock or during the extinction phase. Table 1 sum-
marizes the experimental procedure.
were chosen based on the following considerations: (1) Our previous 
report shows that at these doses, haloperidol, clozapine and olan-
zapine produced a comparable level of disruption on the acquisi-
tion and extinction of avoidance responding, a validated behavioral 
index of anti-psychotic activity, but had no effect on escape (Li et 
al., 2007; Li et al., 2004); (2) all three drugs at these doses also gave 
rise to 50%-70% striatal dopamine D2 occupancy in rats comparable 
to those observed in schizophrenic patients (Kapur et al., 2003a), so 
these doses were considered clinically relevant. The dose of chlordi-
azepoxide (10 mg/kg) was chosen on the basis of the fact that it is 
an effective dose in other aversively conditioned paradigms, such 
as Pavlovian fear conditioning and passive avoidance responding 
(Joordens et al., 1998; Klint, 1991; Nabeshima et al., 1990; Sanger and 
Joly, 1985; Tohyama et al., 1991).
2.4. Statistical analysis 
Passive avoidance latency data and the relative time ratio data 
were expressed as median ± interquartile ranges because they were 
not normally distributed due to ceiling effects, and thus could not be 
analyzed using parametric tests. These data were analyzed using the 
nonparametric Kruskal-Wallis test (>3 groups) or Mann-Whitney 
U test (Decker et al., 1990). Within-group comparisons across days 
were performed using Friedman Test (for more than 3 related sam-
ples) or Wilcoxon Signed Ranks Test (for 2 related samples).
Parametric data such as number of avoidance responses, amount 
of defecations, and body temperature change were expressed as 
mean values ± SEM and were analyzed using a factorial repeated 
measures analysis of variance (ANOVA) with the between-subjects 
factor being treatment condition (“Treatment,” e.g. haloperidol, clo-
zapine, etc.) and the within-subject factor being the test sessions 
(“Session,” e.g. day 1 test, day 2 test, etc.) and Post hoc Tukey HSD 
tests were used to identify the overall group differences. If neces-
sary, one-way ANOVAs were used to identify the group differences 
on each test session. A conventional two-tailed level of significance 
at the 5% level was required.
2.5. Experiment 1: effects of acute haloperidol, clozapine or chlordiazepox-
ide treatment on the acquisition of passive avoidance and conditioned place 
aversion
This experiment was aimed to characterize the behavioral effects 
of acute treatment with haloperidol, clozapine and chlordiazepox-
ide treatment on various conditioned fear responses in a composite 
passive avoidance and conditioned place aversion task, two tradi-
tional behavioral tests that have been widely used to assess anxi-
olytic activity of a drug (Papp, 1988; Sanger and Joly, 1985). This 
task encompasses multiple measures indicative of conditioned 
fear, including passive avoidance response (e.g. passive avoidance 
latency and number of entries to the shock compartment), condi-
tioned place aversion (e.g. the ratio of time spent in the shock com-
partment relative to the time spent in the safe compartment), and 
defecations.
2.5.1. Procedure
A total of 60 rats were randomly assigned to the following 4 
groups: haloperidol, clozapine, chlordiazepoxide or vehicle groups. 
There were 15 rats in each group.
2.5.1.1. Baseline test (habituation). After receiving 5 days of handling 
(approximately 1 min/rat), subjects were placed into the shuttle 
boxes for the baseline test and habituation. The left compartment 
of the shuttle box was decorated with 2-cm horizontal tape stripes 
on the back and front walls and the ceiling, while the right compart-
ment was decorated with vertical stripes, with an automatic guillo-
tine door (ENV-010B) sitting in between. The left compartment also 
had a lightbulb (28 V) in the middle of the sidewall providing illumi-
nation. A subject was first placed in the left compartment (“safe”) at 
the beginning of the test. Thirty seconds later, the door was lifted and 
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3. Results
3.1. Experiment 1: effects of acute haloperidol, clozapine or chlordiazepox-
ide treatment on the acquisition of passive avoidance and conditioned place 
aversion
Haloperidol significantly increased, while chlordiazepoxide sig-
nificantly decreased the passive avoidance latency. On the baseline 
test day and the conditioning day, the latencies to enter the right (“to 
be shocked”) compartment were similar among the 4 groups (all ps > 
0.056, data not shown). However, the passive avoidance latencies on 
the test day were significantly different among the haloperidol, clo-
zapine, chlordiazepoxide and vehicle-treated groups (Kruskal-Wal-
lis tests, p = 0.004). In comparison to the vehicle, chlordiazepoxide 
significantly decreased the passive avoidance latency (Mann-Whit-
ney U test, U = 65.50, p = 0.050), whereas haloperidol significantly 
increased it (U = 65.50, p = 0.050). Clozapine had no significant effect 
on this measure (U = 99.00, p > 0.59). As can be seen in Figure 1, 
when compared to the baseline measures, the passive avoidance 
latencies in both the haloperidol and vehicle groups showed a signif-
icant increase from the baseline day to the test day (Wilcoxon Signed 
Ranks Test, all ps < 0.013). In contrast, the clozapine and chlordiaz-
epoxide groups did not show such a significant change (p = 0.069 
for CLZ and p = 0.91 for CDP), indicating that the inhibitory passive 
avoidance to the shock compartment was attenuated by chlordiaz-
epoxide and, to some extent, by clozapine.
Clozapine and chlordiazepoxide, but not haloperidol, significantly atten-
uated the shock conditioning-induced place aversion. Figure 2 shows the 
median ratios of the time spent in the shock compartment relative 
to the time spent in the safe compartment (Figure 2A) and the mean 
numbers of entries into the shock compartment (Figure 2B) on both 
the baseline habituation day and the post-conditioning test day. 
These two behaviors provide reliable indices of the shock-induced 
conditioned place aversion effect (DiScala and Sandner, 1989; Hola-
han and White, 2004). Clozapine and chlordiazepoxide exhibited a 
very similar behavioral profile on these two measures. In compari-
son to vehicle treatment, both clozapine and chlordiazepoxide signif-
icantly attenuated the shock conditioning-induced decrease on the 
2.6.1.1. Two-way active avoidance training (under drug). Every trial 
started by presenting the CS for 10 s, followed by a continuous 
scrambled footshock (0.8 mA, US, maximum 5 s) on the grid floor. 
If a subject moved from one compartment in to the other within 
the 10 s of CS presentation, it avoided the shock, and this shuttling 
response was recorded as avoidance. If the rat remained in the same 
compartment for more than 10 s and made a crossing upon receiv-
ing the footshock, this response was recorded as escape. If the ani-
mal did not respond during the entire 5 s presentation of the shock, 
the trial was terminated and escape failure was recorded. Intertrial 
intervals varied randomly between 30 and 60 s. Each training session 
lasted about 20 min with a total of 20 trials presented. The number of 
avoidance responses (max: 20) was calculated as the main dependent 
variable for avoidance responding. Fecal matter was collected and 
weighed on a Mettler Toledo scale (< 0.1 mg). An ultrasonic vocal-
ization detector (model number: ANL-937-1) recorded the ultrasonic 
events throughout each session. This detector scans the environment 
every 30 ms and counts any vocalization call with a minimum dura-
tion of 30 ms. We chose to record “22-kHz” calls occurring between 
20 kHz and 32 kHz and above 50 dB because vocalizations within 
this range are often found in rats that are exposed to fearful stimli 
(Wohr et al., 2005) and are sensitive to anxiolytic treatments (San-
chez, 2003). The rat’s body temperature was taken using a probe 
(lubricated with mineral oil) inserted in the rectum (Thermalert 
TH-5, Physitemp, Clifton, NJ, USA) before and after the behavioral 
training/testing and the difference was calculated. The thermistor is 
accurate to 0.1°C.
2.6.1.2. Two-way active avoidance test (drug-free). One day after the last 
training session, all rats were continuously tested drug-free for an 
additional 3 sessions under the CS-alone (no shock) condition. The 
exact same procedure was employed except that the footshock was 
omitted.
2.7. Experiment 3: effects of repeated olanzapine or chlordiazepoxide treat-
ment on conditioned active avoidance responding and various conditioned 
fear responses
The purpose of this experiment was to determine the potential 
anxiolytic effect of olanzapine, a much more widely used drug in 
the clinic. This experiment also used the active avoidance condition-
ing model to examine how repeated olanzapine or chlordiazepoxide 
treatment differentially affected various conditioned fear responses 
in this model. We employed three doses of olanzapine which cov-
ered subclinical, clinical and superclinical doses of olanzapine in 
terms of D2 receptor occupancy (50%-80%) to explore its dose-depen-
dent effect (Kapur et al., 2003b).
2.7.1. Procedure
The exact same procedure as used in Experiment 2 was used. After 
the habituation, the rats were randomly assigned to 5 groups: vehi-
cle (VEH, n = 9), olanzapine 0.5 mg/kg (OLZ 0.5, n = 9), olanzapine 
1.0 mg/kg (OLZ 1.0, n = 9), olanzapine 2.0 mg/kg (OLZ 2.0, n = 9) 
and chlordiazepoxide 10 mg/kg (CDP, n = 9) and tested for 7 days 
under drug and 3 days under drug-free.
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T-Tests, all ps  < 0.015), suggesting that rats did acquire conditioned 
fear after conditioning. In comparison to the vehicle group, defeca-
tions in both the clozapine and chlordiazepoxide groups were signif-
icantly decreased on the conditioning day (Tukey Post hoc, p = 0.000 
for CLZ and 0.041 for CDP), and chlordiazepoxide also decreased 
defecations on the test day (p = 0.016).
3.2. Experiment 2: effects of repeated haloperidol, clozapine or chlordiazep-
oxide treatment on active avoidance responding and various conditioned 
fear responses
Repeated haloperidol and clozapine, but not chlordiazepoxide treat-
ment significantly inhibited avoidance responding during the CAR train-
ing phase. Figure 4A shows the number of conditioned avoidance 
responses in the four groups trained under the drug or vehicle over 
the 7 training days. Both the vehicle and chlordiazepoxide-treated 
rats, but not the haloperidol or clozapine rats, showed a progressive 
across-session increase in avoidance responding, indicating a clear 
learning effect (Repeated Measures ANOVAs: a significant main 
effect of “Treatment”: F(3,34) = 16.011, p < 0.001; “Sessions”: F(6,204) = 
16.822, p < 0.001; and “Treatment” × “Sessions” interaction, F(18,204) 
= 4.761, p < 0.001). In comparison to the vehicle treatment, haloperi-
dol and clozapine, but not chlordiazepoxide, significantly inhibited 
the acquisition of avoidance responding (Tukey Post hoc Tests: HAL 
vs. VEH, p < 0.001; CLZ vs. VEH, p = 0.001; CDP vs. VEH, p = 0.818). 
Most importantly, both drugs did not differ in the magnitude of their 
inhibition during the drug test days (Tukey HSD, p = 0.950), suggest-
ing that at the chosen doses, they exhibited a very similar level of 
anti-psychotic efficacy as this measure is a reliable and sensitive pre-
dictor of anti-psychotic efficacy (Wadenberg and Hicks, 1999).
Figure 4B shows the number of conditioned avoidance responses 
in the three drug-free and CS-alone test days (i.e. extinction). The 
haloperidol group still exhibited significantly lower numbers of 
avoidances than the vehicle group on day 1 (p = 0.008), whereas the 
clozapine group did not (p > 0.270). Data from the clozapine group in 
both the drug training days and the drug-free test days suggest that 
clozapine did not impair the animals’ ability to learn how to actively 
respond to the aversive CS, but only inhibited its expression.
Clozapine and chlordiazepoxide, but not haloperidol, inhibited the 
expression of 22-kHz ultrasonic vocalizations. As can be seen from Fig-
ure 5, during  the 2 habituation days, there were few vocalizations 
recorded. During the 7 CAR training days, only the chlordiazepox-
ide group showed a progressive decrease in the number of 22-kHz 
calls. The haloperidol group had consistently high levels of 22-kHz 
calls, whereas the clozapine group showed consistently lower lev-
els of 22-kHz calls (“Treatment”: F(4,39) = 11.371, p < 0.001; “Sessions”: 
F(6,234) = 2.657, p = 0.016; “Treatment” × “Sessions” interaction, F(24,234) 
= 3.745, p < 0.001). On the first drug test day, clozapine significantly
time spent in the shock compartment (U = 43.00, p = 0.003 for CLZ; 
U = 42.00, p = 0.003 for CDP) and the number of entries into the 
shock compartment on the test day (Tukey Post hoc p = 0.031 and 
0.001 for CLZ and CDP). Haloperidol had little effect (all ps > 0.36). 
Compared to the baseline measures, although the vehicle and halo-
peridol-treated rats decreased their time spent in the shock com-
partment after conditioning (Wilcoxon Signed Ranks Test, p = 0.011 
for the vehicle and p = 0.002 for the haloperidol), the clozapine and 
chlordiazepoxide rats did not (all ps >0.06).
Clozapine and chlordiazepoxide, but not haloperidol, significantly atten-
uated the shock conditioning-induced increase in defecations. Figure 3 
shows the number of defecations across the baseline, conditioning 
and test days. In comparison to the baseline, all four groups showed 
a significant increase in defecations on the test day (Paired samples 
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decreased the 22-kHz calls (p = 0.035 vs. VEH). In comparison to the 
“unconditioned” control group, all conditioned groups showed sig-
nificantly higher numbers of 22-kHz calls during certain drug test 
days (Individual Repeated Measures ANOVAs, all ps < 0.01), sug-
gesting that the footshock did cause fear or anxiety in these groups 
(Wohr et al., 2005). Importantly, during the subsequent 3 drug-
free test days, rats that were previously treated with clozapine and 
chlordiazepoxide still made significantly less 22-kHz calls than did 
the vehicle rats (CLZ: F(1,17) = 7.039, p = 0.017; CDP: F(1,17) = 8.114, p = 
0.011), and their numbers of the 22-kHz calls were not significantly 
different from the “unconditioned” controls (all ps > 0.756). Halo-
peridol rats, like the vehicle controls, still exhibited more 22-kHz 
calls than the “unconditioned” controls (day 1: ps < 0.031; day 2: ps 
< 0.018; day 3: p = 0.42 for VEH and 0.58 for HAL). Because no shock 
was ever presented at this test stage, these 22-kHz calls could be con-
sidered as an acquired “conditioned fear response” to the CS and/or 
to the environment. These results suggest that clozapine and chlordi-
azepoxide, but not haloperidol, do possess an anxiolytic property in 
decreasing this particular conditioned fear response.
Clozapine and chlordiazepoxide inhibited the physiological fear responses 
(e.g. body temperature increase and defecations). Stress-induced hyper-
thermia and defecation is an integral part of an individual’s phys-
iological response to threatening situations and have been used as 
valid tools to screen chemical compounds with anxiolytic property 
(Bruhwyler et al., 1990a; Olivier et al., 2003). Figures 6A and B depict 
the body temperature changes (before and after testing) and the 
amounts of defecation that the rats made throughout the habitua-
tion, CAR training and drug-free test phases. During the habituation 
period, both measures remained low, and no significant group differ-
ence was detected (all ps > 0.05). During the CAR training phase, the 
clozapine and “unconditioned” control groups did not show much 
change in either measure from the habituation days, whereas the 
other three groups increased their body temperatures and amount of 
defecations. Throughout the training sessions, all groups except the 
clozapine group showed a relatively stable level of hyperthermia. On 
the measure of defecations, the haloperidol group appeared to defe-
cate more over the sessions, whereas the vehicle and chlordiazepox-
ide groups defecated progressively less. Repeated Measures ANO-
VAs indicated a significant effect of “Treatment” (body temperature: 
F(4,39) = 18.334, p < 0.001; defecations: F(4,39) = 27.033, p < 0.001), “Ses-
sions” (body temperature: F(6,234) = 3.861, p = 0.001; defecations: F(6,234) 
= 3.977, p = 0.001) and “Treatment” × “Sessions” interactions (body 
temperature: F(24,234) = 3.618, p < 0.001; defecations: F(24,234) = 2.653, p < 
0.001). In comparison to the vehicle treatment, clozapine treatment 
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rats, showed a progressive across-session increase in avoidance 
responding, indicating a clear learning effect (Repeated Measures 
ANOVAs: a significant main effect of “Treatment”: F(4,40) = 15.489, p 
< 0.001; “Sessions”: F(6,240) = 3.506, p = 0.002; and “Treatment” × “Ses-
sions” interaction, F(24,240) = 5.745, p < 0.001). In comparison to the 
vehicle treatment, all three doses of olanzapine, but  not chlordiazep-
oxide, significantly inhibited the acquisition of avoidance respond-
ing (Tukey Post hoc Tests: VEH vs. OLZ 0.5, 1.0, and 2.0 mg/kg, ps 
< 0.001; VEH vs. CDP, p = 0.853). The three doses of olanzapine did 
not differ in their magnitude of inhibition during the drug test days 
(Tukey Post hoc Tests: OLZ 0.5 vs. OLZ 1.0, p =  0.988, OLZ 1.0 vs. 
OLZ 2.0, p = 1.000, OLZ 0.5 vs. OLZ 2.0, p = 0.973), indicating a very 
similar level of anti-“psychotic” efficacy at these doses. Figure  7B 
shows the number of conditioned avoidance responses in the three 
drug-free and CS-alone test days. The three olanzapine-treated 
groups still exhibited significantly lower numbers of avoidances than 
the vehicle group (VEH vs. OLZ 2.0, p = 0.032, vs. OLZ 1.0, p = 0.023, 
vs. OLZ 0.5, p = 0.002) and the chlordiazepoxide group (CDP vs. 
OLZ 2.0, p = 0.001, vs. OLZ 1.0, p = 0.001, and vs. OLZ 0.5, p < 0.001).
significantly inhibited hyperthermia (p < 0.001), and both clozapine 
(p < 0.001) and chlordiazepoxide treatment (p = 0.007) also signifi-
cantly inhibited defecations. In contrast, haloperidol treatment did 
not affect hyperthermia, but did increase the amount of defecation 
on the last training day compared to the vehicle group (p = 0.010).
During the drug-free test phase, although both clozapine and 
chlordiazepoxide-treated rats seemed to defecate less, while the 
haloperidol-treated rats defecated more in comparison to the vehicle 
rats, these effects failed to reach a significant level (all ps > 0.05).
3.3. Experiment 3: effects of repeated dose-dependent olanzapine or chlordi-
azepoxide treatment on conditioned active avoidance responding and vari-
ous conditioned fear responses
Repeated oanzapine treatment, but not chlordiazepoxide, significantly 
inhibited avoidance responding during the CAR training phase and drug-
free test phase. Figure 7A shows the number of conditioned avoidance 
responses in the five groups for the 7 training days. Both the vehicle 
and chlordiazepoxide-treated rats, but not the olanzapine-treated
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Olanzapine and chlordiazepoxide inhibited the physiological fear 
responses (e.g. body temperature increase or defecations). Figures 9A and 
B depict the body temperature changes and amount of defecation 
during the habituation phase, the training phase and the drug-free 
test phase. Both measures were low during the habituation phase, 
with no significant group difference detected (all ps > 0.05). During 
the CAR training phase, there was a clear dose-dependent effect of 
olanzapine treatment on body temperature change. Repeated Mea-
sures ANOVAs revealed a significant main effect of “Treatment” 
(F(4,40) = 7.439, p < 0.001) and a significant main effect of “Sessions” 
(F(6,240) = 3.50, p = 0.002), but no significant “Treatment” × “Sessions” 
interaction (F(24,240) = 0.854, p = 0.665). Post hoc tests showed that 
only the high dose of olanzapine significantly inhibited the body 
temperature increase in comparison to vehicle (OLZ 2.0 vs. VEH: p 
= 0.002). Consistent with the result from Experiment 2, chlordiazep-
oxide did not significantly decrease this measure (Tukey Post hoc, 
CDP vs. VEH, p = 0.07). Low and medium doses of olanzapine were 
also not effective (OLZ 0.5 vs. VEH, p = 0.999; OLZ 1.0 vs. VEH, p 
= 1.00). No group difference was found during the three drug-free 
CS-only test sessions (all ps > 0.05), suggesting that prior olanzap-
ine treatment did not have a long-lasting effect on stress-induced 
hyperthermia.
All three doses of olanzapine, as well as chlordiazepoxide, sig-
nificantly decreased the amount of defecations across the 7 testing 
days (Tukey Post hoc tests: VEH vs. OLZ 0.5, 1.0, and 2.0 mg/kg, p 
< 0.019, 0.002 and 0.001 respectively, VEH vs. CDP, p < 0.035, one-
tailed). Once again, no group difference was found during the three 
drug-free test CS-only test sessions (all ps > 0.05). These results sug-
gest that olanzapine, like chlordiazepoxide, does possess an anx-
iolytic property in decreasing these particular conditioned fear 
responses.
4. Discussion
The present study used two distinct behavioral models and eval-
uated the potential anxiolytic-like activity of typical anti-psychotic 
haloperidol and atypicals clozapine and olanzapine, and compared 
them with that of a classical anxiolyticc hlordiazepoxide. Table 2 
summarizes the results from all experiments. Inspection of this table 
reveals that clozapine and olanzapine show some similarities to 
chlordiazepoxide in terms of their effects on a variety of fear mea-
sures indicative of anxiolytic property. Specifically, clozapine and 
chlordiazepoxide, but not haloperidol, significantly attenuated the 
shock conditioning-induced place aversion, decreased the amount 
of defecations and the number of 22-kHz vocalizations. Clozapine 
also reduced shock conditioning-induced hyperthermia. Similar to 
clozapine, olanzapine also significantly decreased the amount of 
defecations and reduced shock conditioning-induced hyperthermia, 
but it did not inhibit 22-kHz vocalizations. Although it can be said 
that clozapine, olanzapine and chlordiazepoxide all show some anx-
iolytic effects in the fear/anxiety measures in this study, some dif-
ferences did exist. Clozapine significantly decreased the shock con-
ditioning-induced hyperthermia but had no effect on the passive 
avoidance latency, whereas chlordiazepoxide significantly decreased 
the passive avoidance latency but had no effect on body tempera-
ture change. Olanzapine differed from clozapine and chlordiazep-
oxide in that it had no effect on 22-kHz ultrasonic vocalizations at 
the three doses tested. Olanzapine’s anxiolytic property was mainly 
manifested in its effect on hyperthermia and defecations, and this 
effect seems limited to the drug test phase.
Our results also indicate that haloperidol does not seem to pos-
sess any anxiolytic-like property, as tested in these models, but may 
instead possess an anxiogenic-like activity as it increased the passive 
avoidance latency and the amount of defecations.
As mentioned in the Introduction section, evidence so far is vari-
able in regards to the potential anxiolytic property of both typical 
and atypical APDs. Behavioral studies have reported anxiolytic-
like, anxiogenic-like and lack of effects with the use of typical or 
atypical APDs in a broad range of animal models of fear or anxiety 
Olanzapine did not affect the expression of 22-kHz ultrasonic vocal-
izations. As seen in Figure 8, few vocalizations were recorded dur-
ing the habituation days. During the 7 CAR training days, only the 
chlordiazepoxide group showed a progressive decrease on the num-
ber of 22-kHz calls, consistent with the finding from Experiment 
2. However, the difference between the vehicle and the chlordiaz-
epoxide groups was not as large as seen in Experiment 2. Impor-
tantly, none of the three doses of olanzapine inhibited the ultrasonic 
vocalizations. Over all the olanzapine groups actually emitted more 
22-kHz vocalization calls, a profile similar to that of the haloperidol 
group, but dissimilar to that of clozapine, as seen in Experiment 2 
(Repeated Measures ANOVAs: a significant main effect of “Treat-
ment”: F(4,40) = 3.429, p = 0.017; “Sessions”: F(6,240) = 2.970, p = 0.008; 
and “Treatment” × “Sessions” interaction, F(24,240) = 1.946, p = 0.007). 
In the subsequent 3 drug-free test days, although the chlordiazep-
oxide rats showed less 22-kHz calls relative to the vehicle controls, 
the difference was not significant (ps > 0.05). However, the chlordi-
azepoxide rats did show less 22-kHz calls than the olanzapine 0.5 
mg/kg (day 1, p = 0.011; day 2: p = 0.014) and olanzapine 2.0 mg/
kg rats (day 1: p = 0.040).
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stopped, suggesting that both drugs do not affect the memory of 
responding to the CS, but merely inhibit the motivation to respond. 
Our results are also consistent with the finding showing that chlordi-
azepoxide affects declarative memory only, but does not disrupt 
procedural memory (Fang et al., 1987; Nissen et al., 1987). In the cur-
rent study the fear conditioned tasks are concerned with emotional 
memory, rather than spatial learning or memory, which may explain 
the conflicting results that exist. Due to these dissociations found 
between the anxiolytic effect and memory, the anxiolytic activity of 
clozapine and chlordiazepoxide may be separated from any possible 
effect on learning and memory.
Although there is a suggestion that atypical APDs are better than 
typicals in alleviating psychotic fear or anxiety, evidence on this 
issue is still controversial. Most studies either did not directly com-
pare atypicals to typicals (DeVry et al., 1993; Frye and Seliga, 2003) 
or did not find any difference between the two (Fernandez-Tome et 
al., 1979; Inoue et al., 1996; Rasmussen et al., 2001). Even in studies 
that demonstrate atypicals show a superior anxiolytic effect (Siemi-
atkowski et al., 2001), it is not clear whether the observed superiority 
is independent of the irreduced liability to produce akathisia (which 
may look like anxiety) or the intrinsic anxiolytic effects. The second 
contribution of the present study is that we carefully matched the 
anti-psychotic efficacy of haloperidol with clozapine in Experiments 
1 and 2, and with olanzapine in Experiment 3, thus ensuring that 
they were compared under the same conditions so that any behav-
ioral difference between the two cannot be attributed to the influ-
ence from their intrinsic anti-psychotic effect. The way we achieved 
this was by using a dose for each drug that produced a compara-
ble level of disruption on avoidance responding (Li et al., 2004). 
The approach is justified by the well documented fact that avoid-
ance responding is a reliable behavioral index of anti-psychotic effi-
cacy (Wadenberg and Hicks, 1999), and the potency of a drug in the 
avoidance responding test correlates well with its clinical potencies 
(Arnt, 1982). Our results clearly show that under the current experi-
mental conditions, clozapine and olanzapine are indeed superior in 
alleviating a variety of fear-related responses when compared with 
haloperidol.
The 22-kHz USVs are often observed when rats are exposed to 
aversive situations (Antoniadis and McDonald, 1999; Burgdorf et 
al., 2001; Wohr et al., 2005). Previous studies have shown that anxi-
olytics such as diazepam and chlordiazepoxide reduce the number 
of 22-kHz calls (Vivian and Miczek, 1993). The effects of anti-psy-
chotics on this measure are inconsistent, with some studies report-
ing reducing effects (DeVry et al., 1993; Molewijk et al., 1995), some 
reporting no change (Bartoszyk, 1998), and others reporting an 
enhancing effect (Siemiatkowski et al., 2001; Thiessen and Upchurch, 
1981). Our clozapine and chlordiazepoxide results were consistent 
with the literature. The finding that olanzapine failed to decrease 
this measure was inconsistent with Siemiatkowski et al. (2001), who 
reported that acute treatment with olanzapine (1.0 mg/kg) reduced 
the pre-shock contextual vocalizations and tended to diminish the 
post-shock ultrasonic vocalizations. The exact causes of this discrep-
(Ichihara et al., 1988; Ishida-Tokuda et al., 1996; Kovacs and de Wied, 
1978; Thiessen and Upchurch, 1981; Timmerman et al., 1990). One 
contribution of the present study is that we employed two differ-
ent behavioral models of fear/anxiety and multiple measures (both 
behavioral as well as physiological) to examine this issue to ensure 
that our results were not an artifact of a single model or measure. 
Experiment 1 uses a composite passive avoidance and conditioned 
place aversion task, with acute treatment commonly used in these 
paradigms, to evaluate various conditioned fear responses, while 
Experiments 2 and 3 use a two-way active avoidance model to simul-
taneously examine the anti-psychotic properties as well as the con-
ditioned fear responses, using a repeated treatment regimen to best 
mimic clinical features (Li et al., 2007). Results from Experiments 1 
and 2 were consistent in showing that clozapine, but not haloperi-
dol, has a strong anxiolytic activity as it reduced a number of shock 
conditioning-induced fear responses, and results from Experiment 
3 show that olanzapine possesses some anxiolytic properties as it 
reduced shock conditioning-induced hyperthermia and defecations. 
The fact that clozapine and olanzapine share certain anxiolytic effects 
with chlordiazepoxide further strengthens this conclusion. The anx-
iolytic activity of clozapine or olanzapine does not seem to be due to 
their effects on motor functions because rats were tested in the drug-
free condition, and measurements such as the passive avoidance 
latency, body temperature change, and defecations are independent 
of the animals’ motor ability. This activity could not simply be attrib-
uted to their action on constipation (Bhana et al., 2001; Sachdev and 
Saharov, 1998) or core body temperature (Millan et al., 1995; Salmi 
et al., 1994) either, because this anxiolytic effect was observed even 
when the treatment was stopped. We do not think the anxiolytic-like 
activity of clozapine, olanzapine and chlordiazepoxide can be attrib-
uted to the drug effects on associative learning and memory spe-
cifically employed in fear conditioned tasks; however, some stud-
ies have shown that anti-psychotics impair learning and memory 
on various other tasks in rodents. Skarsfeldt (1996) found that sev-
eral typical and atypical anti-psychotics impaired spatial learning in 
the Morris water maze, while other studies have found atypicals to 
cause significant impairment of performance on the radial arm maze 
and in the passive avoidance test (Ortega-Alvaro et al., 2006, Ishi-
yama et al., 2007). However, this memory impairment effect may not 
completely account for our results. Clozapine and chlordiazepoxide-
treated rats acquired the CS-US association as evidenced by the fact 
that all groups of rats showed a significant increase in defecations on 
the test day when they were being placed back into the environment 
where they had received the shock (Experiment 1), and while halo-
peridol significantly impaired the acquisition of avoidance respond-
ing, it did not impair the conditioned fear responses. This conclusion 
is also consistent with other studies showing that APDs generally 
do not impair the learning or even expression of associative condi-
toning (Anisman et al., 1982; Beninger et al., 1980; Li et al., 2004). Li 
et al. (2007) also found that after repeated haloperidol or olanzapine 
treatment in the conditioned avoidance response paradigm animals 
were able to recover avoidance responding after the treatment was
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tions or learning and memory processes. The findings also suggest 
that the combined use of passive avoidance and active avoidance 
conditioning models can be useful in better differentiating typical, 
atypical anti-psychotics and anxiolytics. To some extent, this study 
clarifies certain confusions in the literature regarding the intrinsic 
anxiolytic property of both typical and atypical antipsychotics.
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The neurobiological mechanism(s) of the anxiolytic action of clo-
zapine and olanzapine is poorly understood. Little work has directly 
examined this issue. Recently, there has been indirect evidence sug-
gesting that the effects of clozapine on allopregnanolone, a metabo-
lite of progesterone, may be responsible for its anxiolytic effect. In 
2003 and 2006, Marx et al. found that clozapine and olanzapine can 
dose-dependently increase allopregnanolone in the rat cerebral cor-
tex and hippocampus (Marx et al., 2006a; Marx et al., 2006b; Marx 
et al., 2003). Since allopregnanolone acts as a positive modulator of 
the GABA (A) receptor (Majewska, 1990), and shows a strong anx-
iolytic effect in the elevated plus-maze task and the Geller-Seifter 
conflict test (Akwa et al., 1999; Bitran et al., 2000; Brot et al., 1997), it 
is therefore possible that clozapine or olanzapine-induced elevations 
in allopregnanolone may contribute to their anxiolytic-like effect. 
Using these models and specific pharmacological agents will allow 
one to parse out which of clozapine and olanzapine’s properties are 
critical for thse anxiolytic effects and whether they are completely 
dissociable from its anti-psychotic efficacy.
Results from the present report also suggest interesting behavioral 
dissociations among haloperidol, clozapine, olanzapine and chlordi-
azepoxide with regards to their effects on two categories of con-
ditioned fear responses (e.g. active vs. reactive). Conditioned fear 
responses such as freezing, passively avoiding a “shocked” environ-
ment, or increasing the body temperature, number of 22-kHz USVs, or 
defecations, are innate, reflexive species-typical responses to threats 
and are expressed automatically in the presence of danger, thus they 
are classified as “conditioned reactive fear responses.” Drug effects 
on these measures may indicate an anxiolytic-like or anxiogenic-like 
activity. In contrast, active avoidance to a fearful stimulus requires 
animals to make an overt motor action and is a voluntary and inten-
tional motor response to danger, thus it is deemed as “conditioned 
active fear response” (Amorapanth et al., 2000). An action on the 
active avoidance response is a well-established indicator of anti-psy-
chotic-like activity (Wadenberg and Hicks, 1999). Collectively, our 
results suggest that haloperidol, atypical APD blocking dopamine 
D2 receptors, selectively disrupts active avoidance response but has 
little or even an enhancing effect on conditioned reactive fear. Anxi-
olytic chlordiazepoxide, an agonist on benzodiazepine/GABA com-
plex receptor system, inhibits conditioned reactive fear at doses that 
have no effecton active avoidance consistent with its exclusive sed-
ative hypnotic profile. Clozapine and olanzapine, the multi-recep-
tor blocking atypical anti-psychotics, have inhibitory effects on both 
types of fear responses, indicating a dual efficacy against both fear 
and psychosis. It would be interesting to explore other APDs and 
anxiolytics and see whether they conform to these dissociations.
The present study has several limitations. First, we did not exam-
ine the dose-response effect of clozapine or haloperidol. Only one 
dose for each of these drugs was tested, though we attempted to 
explore this issue with olanzapine. This issue will be addressed in 
the next study. It is well-known that  the same drug can have quite 
different behavioral effects at different dosage levels (Murphy and 
Feldon, 2000). It is thus possible that haloperidol might even show 
an anxiolytic activity when tested at a lower dose. However, because 
our haloperidol dose is considered to be clinically relevant in terms 
of its effect on dopamine D2 occupancy and on avoidance respond-
ing (Kapur et al., 2003b), it could be said that at least haloperidol 
has little anxiolytic effect at the clinically relevant doses. Second, we 
did not examine how sensitive and reliable our models are in com-
parison to other established animal models of fear and anxiety such 
as elevated plus-maze. Third, we only examined how anti-psychotic 
treatment affects the acquisition of conditioned fear, not its reten-
tion and extinction.
In summary,the present study demonstrates that atypical APDs 
such as clozapine and olanzapine do possess a certain degree of 
anxiolyitic efficacy. This additional efficacy is not attributable to its 
superior anti-psychotic effect or its favorable effects on motor func-
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